Neurocrine Biosciences Inc vs SK Hynix — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while SK Hynix trades at $169.03 (market cap $891.31B). The key difference: SK Hynix is far larger — about 62.1× Neurocrine Biosciences Inc's market cap, and SK Hynix pays a 0.06% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and SK Hynix for 10 Days on average.
| NBIX | SKHY | |
|---|---|---|
Market Cap | $14.36B | $891.31B |
Volume | 1,237,180 | 22,268,296 |
Sector | Health | Technology |
52-Week High | $185.50 | $198.63 |
52-Week Low | $123.10 | $126.79 |
Typical Hold Time | 23 Days | 10 Days |
Enterprise Value | $14.37B | $841.45B |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SK hynix is a South Korean semiconductor company that manufactures memory products, including DRAM and NAND flash. Its high-bandwidth memory (HBM) products are designed for high-performance computing and AI applications.
Read more on SKHY →